Gossamer Bio Inc. (Ticker: GOSS) recently disclosed the topline data from its Phase III clinical trial, the Prosera study.
Show original
Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!
A welcome pack worth 6200 USDT for new users! Sign up now!
The study aims to evaluate the efficacy and safety of the candidate drug Seralutinib in patients with pulmonary arterial hypertension. The results of this pivotal study mark a significant advancement for the company in the field of pulmonary arterial hypertension treatment. The release of topline data provides a key basis for subsequent research and development decisions, and will also influence the drug's marketing application strategy. As a rare and severe disease, pulmonary arterial hypertension still has unmet clinical needs. If ultimately approved, Seralutinib is expected to offer a new treatment option for patients.
0
0
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
Understand the market, then trade.
Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.
Trade now!
You may also like
RootData: BIO will unlock tokens worth about $1 million in one week
Chaincatcher•2026/09/26 09:03

Grayscale Files Zcash ETF That Pays Every 2 Weeks: What's the Catch?
BeInCrypto•2026/09/26 08:18
FET Bulls Eye $9 As Weekly Chart Flashes a Familiar Setup
DailyCoin•2026/09/26 07:57
Crypto prices
MoreBitcoin
BTC
$84,163.85
-1.23%
Ethereum
ETH
$2,687.22
-1.95%
Tether USDt
USDT
$0.9998
-0.01%
BNB
BNB
$774.15
-0.89%
XRP
XRP
$1.55
-1.60%
USDC
USDC
$0.9999
+0.01%
Solana
SOL
$120.37
-1.06%
TRON
TRX
$0.3369
-0.07%
Zcash
ZEC
$1,534.55
-4.86%
Hyperliquid
HYPE
$92
-2.34%
How to buy BTC
Bitget lists BTC – Buy or sell BTC quickly on Bitget!
Trade now
Become a trader now?A welcome pack worth 6200 USDT for new users!
Sign up now